Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evorpacept + trastuzumab + capecitabine
- Development stage
- Unknown
- Lead developer
- ALX Oncology
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Evorpacept + trastuzumab + capecitabine is an investigational combination therapy currently in clinical trials for the treatment of advanced or metastatic HER2-positive breast cancer. **Evorpacept** (code name ALX148) is a high-affinity CD47-blocking antibody-protein fusion that disrupts the "do-not-eat-me" signal, thereby promoting phagocytosis of tumor cells by macrophages, especially when combined with immune-active Fc-containing antibodies like trastuzumab. **Trastuzumab** is a humanized monoclonal antibody targeting HER2 receptors, inhibiting cell proliferation signaling and mediating antibody-dependent cellular cytotoxicity (ADCC). **Capecitabine** is a cytotoxic antimetabolite chemotherapy prodrug converted to fluorouracil, which inhibits DNA synthesis and tumor cell proliferation. The combination leverages enhanced tumor cell phagocytosis (evorpacept), HER2-specific cytotoxic targeting (trastuzumab), and direct cell killing (capecitabine). Primary indications in clinical trials include metastatic HER2-positive breast cancer, with ongoing studies also examining advanced gastrointestinal cancers. The developer and lead sponsor is ALX Oncology[6][1][2].
- Other names
- evorpacept + trastuzumab + capecitabine
02
Targets
CD47 (Cluster of Differentiation 47)TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on evorpacept + trastuzumab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evorpacept + trastuzumab + capecitabine.